BMS-566419（Cat No.:I004526）is a selective and orally active inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme that converts inactive cortisone to active cortisol in metabolic tissues. By reducing intracellular cortisol levels, BMS-566419 modulates glucocorticoid signaling, which plays a key role in glucose homeostasis, lipid metabolism, and insulin sensitivity. It has been investigated as a potential therapeutic agent for metabolic disorders such as type 2 diabetes, obesity, and metabolic syndrome. BMS-566419 serves as a valuable tool for studying 11β-HSD1-related pathways and developing targeted treatments for metabolic dysfunction.